News & Updates

Monthly injections of the investigational biologic garadacimab substantially reduced the mean attack rate in patients with hereditary angioedema (HAE) in the phase III VANGUARD trial.

Inhibiting the pathways of both epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) leads to significant improvements in progression-free survival (PFS) but more adverse events (AEs), results of a meta-analysis have shown.

Offspring born to mothers with Crohn’s disease (CD), but not ulcerative colitis, are at higher risk of infection, suggests a study. This association is partly mediated by adverse birth outcomes and antitumour necrosis factor α (anti-TNFα) agents.

Adding pembrolizumab to chemotherapy consisting of ifosfamide, carboplatin, and etoposide (ICE) in the treatment of patients with relapsed or refractory classic Hodgkin lymphoma appears to be well tolerated and associated with better outcomes in comparison with reports from studies on chemotherapy-only regimens, according to data from a phase II study.

Higher concentrations of infliximab postinduction results in favourable clinical outcomes in paediatric patients with Crohn’s disease (CD) both in the short and long term, reports a study.

Adding vistusertib to weekly paclitaxel does not appear to help improve clinical outcomes in patients with platinum-resistant or refractory ovarian high-grade serous carcinoma (PR-HGSC), according to the results of a phase II study.

Among patients with lymphoma receiving anthracycline-based chemotherapy, those who received atorvastatin for 12 months were significantly less likely to experience a cardiac dysfunction than those on placebo, according to the STOP-CA* trial presented at ACC.23/WCC.